Comparative in vitro activity of cefoxitin, cefotaxime alone, and in combination with desacetylcefotaxime against the Bacteroides species

Aldridge, 1984, In vitro synergy and potentiation between cefotaxime and desacetylcefotaxime against clinical isolates of Bacteroides, Diagn Microbiol Infect Dis, 2, 47s Chin, 1984, Cefotaxime and desacetylce-fotaxime: an example of advantageous antimicrobial metabolism, Diagn Microbiol Infect Dis, 2, 21s Coombs, 1982, Metabolism of cefotaxime in animals and humans, Rev Infect Dis, 4, S325, 10.1093/clinids/4.Supplement_2.S325 Cuchural, 1984, Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: Comparison of 1981 with 1982, Antimicrob Agents Chemother, 16, 145, 10.1128/AAC.26.2.145 Doluisio, 1982, Clinical pharmacokinetics of cefotaxime in patients with normal reduced renal function, Rev Infect Dis, 4, S333, 10.1093/clinids/4.Supplement_2.S333 Fu, 1979, Pharmacokinetics of cefotaxime, Antimicrob Agents Chemother, 16, 592, 10.1128/AAC.16.5.592 Hall, 1983, The fractional inhibitory concentration (FIC) index as a measure of synergy, J Antimicrob Chemother, 11, 427, 10.1093/jac/11.5.427 Jenkins, 1982, Differences in susceptibilities of species of the Bacteroides fragilis group to several B. lactam antibiotics: Indole production as an indicator of resistance, Antimicrob Agents Chemother, 22, 628, 10.1128/AAC.22.4.628 Jones, 1984, The activity of cefotaxime and desacetylcefotaxime alone and in combination against anaerobes and staphylococci, Diagn Microbiol Infect Dis, 2, 37S Jones, 1982, Antimicrobial activity of desaceylcefotaxime alone and in combination with cefotaxime: Evidence of synergy, Rev Infect Dis, 4, S366, 10.1093/clinids/4.Supplement_2.S366 Jones, 1982, Antimicrobial activity of amikacin combinations against Enterobacteriaceae moderately susceptible to third generation cephalosporins, Antimicrob Agents Chemother, 22, 985, 10.1128/AAC.22.6.985 Jones, 1982, Cefotaxime: A review of in vitro antimicrobial properties and spectrum of activity, Rev Infect Dis, 4, S300, 10.1093/clinids/4.Supplement_2.S300 Jorgensen, 1980, In vitro activities of CTX and moxalactam (LY127935) against aerobic gram-negative bacilli, Antimicrob Agents Chemother, 17, 937, 10.1128/AAC.17.6.937 Luthy, 1979, Human pharmacology of cefotaxime (HR 756), a new cephalosporin, Antimicrob Agents Chemother, 16, 127, 10.1128/AAC.16.2.127 National Committee for Clinical Laboratory Standards, 1985, 5, 18 Neu, 1977, Mecillinam—an amidino penicillin which acts synergistically with other β-lactam compounds, J Antimicrob Chemother, 3, 43, 10.1093/jac/3.suppl_B.43 Neu, 1982, Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime, Rev Infect Dis, 4, S374, 10.1093/clinids/4.Supplement_2.S374 Novick, 1982, Levels of cefotaxime in body fluids and tissues: A review, Rev Infect Dis, 4, S346, 10.1093/clinids/4.Supplement_2.S346 O'Keefe, 1987, Activity of newer β-lactum agents against clinical isolates of Bacteroides species, Antimicrob Agents Chemother, 31, 2002, 10.1128/AAC.31.12.2002 Smith, 1986, Comparison of agar dilution, microdilution, and disk elution methods for measuring the synergy of cefotoxime and its metabolite against anaerobes, J Clin Microbiol, 23, 1104, 10.1128/JCM.23.6.1104-1108.1986 Tally, 1983, Nationwide study of the susceptibility of the Bacteroides fragilis group in the United States, Antimicrob Agents Chemother, 28, 675, 10.1128/AAC.28.5.675 Trang, 1985, Cefotaxime and desacelylcefotaxime pharmacokinetics in infants and children with meningitis, Antimicrob Agents Chemother, 28, 791, 10.1128/AAC.28.6.791